FDA approves Xermelo for carcinoid syndrome diarrhea

The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.

“Today’s approval will provide patients whose carcinoid syndrome diarrhea is not adequately controlled with another treatment option,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

This new treatment is now available by prescription and will be in select specialty pharmacies beginning March 6, 2017.

To read more about the approval click here for the FDA's release or here for the Lexicon press release.

For those needing information on how to getting Xermelo please click here.